<DOC>
	<DOCNO>NCT00524368</DOCNO>
	<brief_summary>The purpose study test treat darunavir/ritonavir ( DRV/rtv ) 800/100 mg daily effective treat DRV/rtv 600/100 mg twice daily , early antiretroviral ( ARV ) -experienced patient give along select optimize background regimen ( OBR ) .</brief_summary>
	<brief_title>A Study Compare Effectiveness Safety Darunavir/Ritonavir ( DRV/Rtv ) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily Early Treatment-Experienced HIV-1 Infected Patients ( ODIN )</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , open-label ( people know identity intervention ) study 590 patient randomly assign receive either DRV/rtv 800/100 mg daily DRV/rtv 600/100 mg twice daily along select OBR . An OBR consist least 2 nucleoside reverse transcriptase inhibitor ( NRTIs ) select investigator . The study include 4 week screening period , 48-weeks treatment period 4-weeks follow-up . The study also consist extension phase Week 48 : region DRV yet commercially available reimburse health care system , patient complete 48 week treatment DRV/rtv continue benefit treatment , opportunity continue DRV treatment 600 mg twice daily dosage DRV reimburse available via public and/or private health care system development discontinue . Safety evaluation consist adverse event ( include specific toxicity ) , clinical laboratory test , vital sign , electrocardiogram , physical skin examination .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Patients document human immunodeficiency virus Type 1 ( HIV1 ) infection Patients viral load great 1,000 HIV1 ribonucleic acid ( RNA ) copies/mL Stable highly active antiretroviral therapy ( HAART ) regimen least 12 week screen In investigator 's opinion , nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) valid treatment option , patient 's antiretroviral ( ARV ) treatment history , ARV resistance testing , medicationtaking behavior , safety tolerability concern , patientrelated factor Prescreening or/and screen plasma HIV1 RNA great 1,000 copies/mL HAART regimen screen Presence currently active condition fit definition World Health Organization ( WHO ) Clinical Stage 4 , follow exception : stable cutaneous kaposi 's sarcoma ( ie , internal organ involvement oral lesion ) unlikely require form systemic therapy study time period , waste syndrome Patients investigational ARV part current regimen , follow exception applicable ( depend local regulatory approval ) : tenofovir , emtricitabine Previous current use enfuvirtide ( ENF ) , tipranavir and/or DRV Life expectancy le 12 month Pregnant breastfeed female Any active clinically significant disease ( eg , tuberculosis [ TB ] , cardiac dysfunction , pancreatitis , acute viral infection ) finding screen medical history physical examination , investigator 's opinion , would compromise patient 's safety outcome study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Human immunodeficiency virus - type 1</keyword>
	<keyword>HIV-1 Infection</keyword>
	<keyword>TMC-114</keyword>
	<keyword>Darunavir</keyword>
	<keyword>Ritonavir</keyword>
</DOC>